Skip to main content
AAPL+0.11%NVDA+1.04%MSFT+0.14%GOOGL+0.78%AMZN+0.26%TSM+6.33%SPCX+8.62%META+0.27%TSLA+0.40%AVGO+0.74%LLY-0.79%BRK-B-0.25%WMT-1.72%SKHY+2.78%JPM-0.84%V+0.01%MU+0.42%AMD+11.04%XOM+0.34%JNJ+1.43%MA-0.49%ASMLa+2.69%ABBV+1.07%0700.HK-0.26%1398.HK-0.16%COST-1.13%CVX-0.15%KO-0.06%PG-1.02%CSCO-1.95%0939.HK+0.14%UNH-0.40%ORCL+0.82%HD-1.85%BAC-0.68%GE+2.70%3988.HK+0.08%1816.HK+1.93%0857.HK-0.29%1288.HK+0.15%PM-1.80%NVS+0.38%0005.HK+0.61%INTC+7.71%HSBA.L-0.21%AZN-0.22%MS-0.55%SAPd-2.32%9988.HK-0.15%ORp-1.27%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURDKK0.00%EURUSD0.00%CHFJPY0.00%EURNZD0.00%EURJPY0.00%NZDMXN0.00%EURNOK0.00%GBPCHF0.00%EURCAD0.00%PLNJPY0.00%CHFNOK0.00%USDHKD0.00%USDZAR0.00%USDPLN0.00%AUDCHF0.00%CADJPY0.00%EURSEK0.00%GBPUSD0.00%GBPCAD0.00%USDDKK0.00%GBPAUD0.00%GBPNZD0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%GBPZAR0.00%NZDCAD0.00%GBPSGD0.00%EURPLN0.00%W10.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.29%ETHUSD+28.67%USDTUSD-0.02%XRPUSD+27.34%SOLUSD+31.48%TRXUSDT+0.33%ZECUSDT-0.37%DOGEUSD+30.64%XMRUSDT+0.54%LINKUSD+0.35%BCHUSDT-0.73%XLMUSD+0.30%UNIUSD+2.54%LTCUSD+27.23%SUIUSD+0.52%HBARUSDT+0.64%TONUSD+56.05%TAOUSDT+1.57%AAVEUSD+1.32%DOTUSDT+0.77%ICPUSDT+0.71%ONDOUSDT-0.07%ARBUSDT+1.22%WLDUSDT+2.43%INJUSDT+0.42%JUPUSDT-0.90%ATOMUSDT-0.23%STXUSDT-0.61%TIAUSDT+1.10%PYTHUSDT-2.64%FETUSDT+0.29%SEIUSDT-0.64%IMXUSDT+0.05%GRTUSDT-0.86%OPUSDT-0.05%POLUSDT-0.71%WIFUSDT-0.73%IOTAUSDT-0.63%AXSUSDT-0.06%EOSUSDT+1.11%FARTCOINUSDT+3.93%DYDXUSDT-0.44%GALAUSDT-0.50%ORDIUSDT+4.50%RONINUSDT+3.92%NOTUSDT+5.35%AAPL+0.11%NVDA+1.04%MSFT+0.14%GOOGL+0.78%AMZN+0.26%TSM+6.33%SPCX+8.62%META+0.27%TSLA+0.40%AVGO+0.74%LLY-0.79%BRK-B-0.25%WMT-1.72%SKHY+2.78%JPM-0.84%V+0.01%MU+0.42%AMD+11.04%XOM+0.34%JNJ+1.43%MA-0.49%ASMLa+2.69%ABBV+1.07%0700.HK-0.26%1398.HK-0.16%COST-1.13%CVX-0.15%KO-0.06%PG-1.02%CSCO-1.95%0939.HK+0.14%UNH-0.40%ORCL+0.82%HD-1.85%BAC-0.68%GE+2.70%3988.HK+0.08%1816.HK+1.93%0857.HK-0.29%1288.HK+0.15%PM-1.80%NVS+0.38%0005.HK+0.61%INTC+7.71%HSBA.L-0.21%AZN-0.22%MS-0.55%SAPd-2.32%9988.HK-0.15%ORp-1.27%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%EURDKK0.00%EURUSD0.00%CHFJPY0.00%EURNZD0.00%EURJPY0.00%NZDMXN0.00%EURNOK0.00%GBPCHF0.00%EURCAD0.00%PLNJPY0.00%CHFNOK0.00%USDHKD0.00%USDZAR0.00%USDPLN0.00%AUDCHF0.00%CADJPY0.00%EURSEK0.00%GBPUSD0.00%GBPCAD0.00%USDDKK0.00%GBPAUD0.00%GBPNZD0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%CADCHF0.00%NZDJPY0.00%GBPZAR0.00%NZDCAD0.00%GBPSGD0.00%EURPLN0.00%W10.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.29%ETHUSD+28.67%USDTUSD-0.02%XRPUSD+27.34%SOLUSD+31.48%TRXUSDT+0.33%ZECUSDT-0.37%DOGEUSD+30.64%XMRUSDT+0.54%LINKUSD+0.35%BCHUSDT-0.73%XLMUSD+0.30%UNIUSD+2.54%LTCUSD+27.23%SUIUSD+0.52%HBARUSDT+0.64%TONUSD+56.05%TAOUSDT+1.57%AAVEUSD+1.32%DOTUSDT+0.77%ICPUSDT+0.71%ONDOUSDT-0.07%ARBUSDT+1.22%WLDUSDT+2.43%INJUSDT+0.42%JUPUSDT-0.90%ATOMUSDT-0.23%STXUSDT-0.61%TIAUSDT+1.10%PYTHUSDT-2.64%FETUSDT+0.29%SEIUSDT-0.64%IMXUSDT+0.05%GRTUSDT-0.86%OPUSDT-0.05%POLUSDT-0.71%WIFUSDT-0.73%IOTAUSDT-0.63%AXSUSDT-0.06%EOSUSDT+1.11%FARTCOINUSDT+3.93%DYDXUSDT-0.44%GALAUSDT-0.50%ORDIUSDT+4.50%RONINUSDT+3.92%NOTUSDT+5.35%
GS

Gilead Sciences, Inc. (GILD)

NASDAQ • Healthcare

$166.89
-$0.68 (-0.4%)
Market closed

November 6, 2026 at 21:00 UTC

Open$164.11
Day Range$164 - $169.03
Avg. Volume (3M)7M
Market Cap$207B
52 Week Range
$116.88$176.58

Interactive Chart

07:35:12 UTC

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$8.3B100%
Gross Profitminus cost of goods$6.7B81%
Operating Incomeminus R&D and overhead$3.4B42%
Net Incomeminus taxes and the rest$2.4B29%

In plain terms: out of every $100 in revenue, Gilead Sciences, Inc. keeps $29 as net profit.

Fundamentals & Financials

Revenue (TTM)
$30.9B
Net Income (TTM)
-$3.8B
EPS (TTM)
-$3.1
ROA (TTM)
-7.51%
Current Ratio
1.38
Dividend Yield
0.56%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+6.3%Q2 2026$2.03
+6.9%Q3 2026-$6.75
+16.4%Q4 2026$2.55

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +16.4%

Gilead Sciences topped revenue expectations on preliminary second fiscal quarter of 2026 results reported Aug. 4, as revenue rose 10.2% to about $7.8 billion from $7.08 billion a year ago and beat the about $7.4 billion consensus by 5.5%. Total product sales, the largest segment, rose 5.0% to about $7.0 billion, while the U.S. remained the biggest geographic concentration at about $4.9 billion, up 5.5%. Gross profit came in at roughly $6.2 billion and gross margin held near 80%, with operating cash flow of $3.57 billion and $1.04 billion paid in dividends. Consensus for the next period calls for EPS of $2.16 on revenue of $7.76 billion.

View full earnings history

About Gilead Sciences, Inc.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines for critical health needs and trades on the NASDAQ as GILD. The biopharmaceutical company sits in healthcare, with FY2025 revenue of $29.4 billion, and its portfolio spans antiviral therapies, oncology and cell therapy products, and specialty cardiovascular treatments.

Name
Gilead Sciences, Inc.
CEO
Daniel O'Day
Industry
Healthcare
Year Founded
1987
Employees
17,000

Today's Snapshot

AI-generated

The day ended with GILD slightly lower at 166.89, in line with a flat sector. Gilead Sciences faced regulatory hurdles as new evidence emerged for Livdelzi, its liver-disease drug.

Trading Volume

Below 10d avg (7.8M)

5.6M

vs S&P 500 Today

Underperforming Market

-0.81%

Updated: November 6, 2026 at 21:19 UTC

Technical Indicators

6 Buy2 Neutral0 Sell
GILD is trading at 166.89 and shows a constructive technical picture: the price sits above its short- and medium-term moving averages as well as the 200-day, while MACD and short EMAs signal bullish momentum. ADX around 30 indicates a meaningful trend, and momentum readings are supportive rather than stretched, with RSI and CCI in neutral-to-positive territory; volume via OBV is positive, reinforcing accumulation. Volatility is moderate, reflected in a contained ATR, and classic pivots are nearby but not decisive. Technical takeaway: Strong Buy — trend and momentum are aligned in favor of bulls.
All signals
  • EMA (5 indicators)$141.62 - $165.85
    Buy
  • RSI (14)60.24
    Neutral
  • Stochastic %K (14, 3, 3)73.31
    Neutral
  • MACD Level (12, 26)5.29
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.